Tremfya
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis
The drug is the first IL-23 inhibitor approved for children from the age of six
Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis
Approximately 125 million people globally are living with some form of psoriasis
FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis
The Stelara biosimilar now offers all dosage forms and strengths of its reference product
J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis
Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK
Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis
More than 2.5 million people in Europe are affected by the inflammatory bowel disease
Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults
More than 2.5 million people in Europe are living with the inflammatory bowel disease
Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis
The inflammatory condition affects approximately 30% of psoriasis patients
Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease
Inflammatory bowel disease is estimated to affect nearly two million people across Europe
LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe
Approximately 125 million people worldwide are affected by some form of the inflammatory condition
Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease
An estimated three million people in the US are affected by inflammatory bowel disease
J&J receives three CHMP recommendations for immunology and oncology indications
Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively